cardiovascular drugs market in ksa & uae
DESCRIPTION
Frost & Sullivan Analyst Briefing Presentation on 'Cardiovascular Drugs Market in KSA & UAETRANSCRIPT
Cardiovascular Drugs Market in KSA & UAE- What’s in store for Pharmacos?
Supratim Majumdar, Industry Manager
Healthcare
20th April, 2011
2
Today’s Presenters
Supratim Majumdar, Industry Analyst
Frost & Sullivan
Tanu Chopra, Assistant Manager, Corporate Communications,Frost & Sullivan
3
Research Aim and Key Deliverables
Research Aim
• The aim of this research service is to present an analysis of the Cardiovascular Drugs Market
in KSA and UAE.
Key Deliverables
• Quantifying the size and growth forecasts of the cardiovascular drugs market in KSA and
UAE from 2010 to 2017 by product segments
• Providing insight into the industry challenges, market drivers, and market restraints during the
forecast period
• Identifying key participants of the market and quantifying company market shares by product
segments
• Providing further insight into the competitive environment
• Identifying opportunities for current and new market participants based on a strength,
weakness, opportunities, and threats (SWOT) analysis
4
Market Scope and Segmentation
Market Scope:
Countries covered for the study are:
� Kingdom of Saudi Arabia (KSA)
� United Arab Emirates (UAE)
Market Segmentation:
Antihypertensive
Antidyslipidemic
OthersMark
et
Segm
ents Antihypertensive
Antidyslipidemic
Others
Antihypertensive
Antidyslipidemic
5
Market Overview
� Cardiovascular disease (CVD) is the main cause of disability and premature death through the world in general and in KSA and UAE in particular.
� KSA and UAE population is achieving high percentages of cardiovascular diseases prevalence, due to sedentary lifestyle, mimicking western food habits, smoking, etc.
� The total KSA cardiovascular drugs market generated revenue of $172.8 million in 2010.Revenues are expected to increase to $537.1 with a CAGR of 17.6 percent.
� The total UAE cardiovascular drugs market generated revenue of $100.2 million in 2010.Revenues are expected to increase to $292.4 million with a CAGR of 16.5 percent.
� Within the market, antihypertensives held the largest share of almost 60.0 percent of the revenues in 2010, followed by antidyslipidemics, which help a 37.0 percent share and the others segment with around a share of 3.0 percent.
6
Market Overview Contd.
� At present, there are around 16 players competing in the KSA market. Around 80.0 of the total market is controlled by top 4 players.
� In UAE, around 11 participants are competing in the cardiovascular drugs market. Top 4 players command around 60.0 percent of the market.
� Within antihypertensives, ACE Inhibitors and ARBs are most preferred and used drug classes in both of the markets.
� Statins is the undisputed most used drug class among antidyslipidemics in both the markets.
� Foreign pharmaceutical companies command the majority market share due to innovative products, generic coverage by local companies, fewer number of local companies with limited manufacturing capacity.
7
Market Drivers and Restraints
Long TermLong TermMid TermMid TermShort TermShort Term
Dri
vers
Restr
ain
ts
Rising incidence of life style diseases
Mandatory health insurance
Rising ageing population
Rising health awareness
Newer & easier launches of combination drugs
Rising incidence of life style diseases
Mandatory health insurance
Rising incidence of life style diseases
Mandatory health insurance
Patent expiry and launches of lesser value generics
Government promoting usage of generics
Stringent regulatory system
Low patient compliance
8
Current Market Size and Growth Trends: KSA
Cardiovascular Drugs Market: Revenue Forecast (KSA), 2010 - 2017
0
100
200
300
400
500
600
Years
Mark
et R
evenue (M
illion U
SD
)
Market Revenue(Million USD) 173 537
2010 2017
9
Cardiovascular Drugs Market – Segment Analysis: KSA
Cardiovascular Drugs Market: Market Segments (KSA), 2010
Others 3%
Antihypertensive 60%
Lipid Lowering 37%
10
Market Share Analysis: KSA
Total Cardiovascular Drugs Market: Market Share Analysis (KSA), 2010
Top 4 Players
80%
Others
20%
Top 4 Players
80%
Others
20%
11
Cardiovascular Drugs Market: Revenue Forecast (UAE), 2010 - 2017
0
100
200
300
Years
Mark
et R
evenue (M
illion U
SD
)
Market Revenue(Million USD) 100 292
2010 2017
Current Market Size and Growth Trends: UAE
12
Others,
2.41%
Lipid
Lowering,
36.54%
Anti
Hypertensive
61.2 %
Cardiovascular Drugs Market Segment (UAE), 2010
Cardiovascular Drugs Market – Segment Analysis: UAE
13
Market Share Analysis: UAE
Total Cardiovascular Drugs Market: Market Share of Key Players (UAE), 2010
Top 4 Players
80%
Others
20%
14
Next Steps
� Request a proposal for or Growth Partnership Services or Growth Consulting Services to support you and your team to accelerate the growth of your company. ([email protected]) 1-877-GoFrost (1-877-463-7678)
� Join us at our annual Growth, Innovation, and Leadership 2011: A Frost &
Sullivan Global Congress on Corporate Growth (www.gil-global.com)
� Register for the next Chairman’s Series on Growth: Driving Innovation – The What, Why, and How. Visions and Benchmarks as the Innovation Key
(October 5th) (http://www.frost.com/growth)
� Register for Frost & Sullivan’s Growth Opportunity Newsletter and keepabreast of innovative growth opportunities(www.frost.com/news)
15
Your Feedback is Important to Us
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by rating this presentation.
What would you like to see from Frost & Sullivan?
Frost & Sullivan’s Growth Consulting can assist with your growth strategies
16
http://twitter.com/frost_sullivan
Follow Frost & Sullivan on Facebook, LinkedIn, SlideShare, and Twitter
http://www.facebook.com/FrostandSullivan
http://www.linkedin.com/companies/4506
http://www.slideshare.net/FrostandSullivan
17
For Additional Information
Supratim Majumdar
Industry Analyst
Healthcare
(033) 6160-6666
Anish Charles
Asst Manger Corporate Communications – South Asia
(91) 22 66072019
Dr. Ajay Prasad Sharma
Industry Manager
Healthcare
(022) 6160-6666
Tanu Chopra
Asst. Manager - Corporate Communications - MENA
(91) 22 66072037